NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Dolutegravir市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Dolutegravir Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008266
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Dolutegravir市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Dolutegravir Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

中國市場中Dolutegravir,從2016年到2020年期間以166.14%的年複合成長率成長,銷售額有增加趨勢。Dolutegravir的良好耐受性,藥物抗性,服用的便利性等的優點,在中國市場的銷售額急速成長,從2016年的20萬人民幣到2017年增加到314萬人民幣,年度成長率成為1392.89%。可是,2020年,Dolutegravir的銷售額減少12.92%,主要理由,是COVID-19流行給予醫院的診斷、治療事業整體影響。

隨著愛滋病患者數增加,Dolutegravir的銷售額從2021年到2025年增加。由於COVID-19流行有效緩和,Dolutegravir的銷售額預計從2021年到2025年恢復成長。

本報告提供中國的Dolutegravir市場的相關調查,市場規模和預測,趨勢,COVID-19的影響,價格,成長要素和機會,威脅,課題,市場佔有率等資訊。

目錄

第1章 Dolutegravir的相關概念

  • Dolutegravir的適應症
  • 中國的Dolutegravir的開發
  • 中國的Dolutegravir的政府核准
  • COVID-19對中國的Dolutegravir銷售的影響

第2章 中國的Dolutegravir銷售(2016-2020)

  • Dolutegravir的銷售量
    • 總銷售額
    • 各地區的銷售量
  • Dolutegravir的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Dolutegravir銷售(2016-2020)
    • 錠劑
    • 其他的劑型分析

第3章 中國的主要Dolutegravirmeka分析(2016-2020)

  • 主要Dolutegravirmeka的市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • ViiV Healthcare BV
    • 企業簡介
    • 中國的TIVICAY(ViiV Healthcare BV的Dolutegravir)銷售
  • 其他企業分析

第4章 中國的各製造商Dolutegravir的價格(2020-2021)

  • ViiV Healthcare BV (TIVICAY)
  • 其他企業分析

第5章 中國的Dolutegravir市場預測(2021-2025)

  • 中國的Dolutegravir市場開發的有影響力的要素
    • COVID-19對中國的Dolutegravir市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105501

Dolutegravir was developed by GlaxoSmithKline for the treatment of HIV-infected adults and children over 12 years old. Its product TIVICAY was approved in China in 2016 and was approved for children's indications in China in 2019. As of the first half of 2021, ViiV Healthcare BV is the only manufacturer in the Chinese Dolutegravir market.

According to CRI's market research, the sales of Dolutegravir in the Chinese market have had an upward trend from 2016 to 2020. Due to the advantages of Dolutegravir, such as good tolerability, drug resistance, and convenience of taking drugs, its sales in the Chinese market have grown rapidly, from CNY0.2 million in 2016 to CNY3.14 million in 2017, with an annual growth rate of 1392.89%. In 2020, sales of Dolutegravir fell by 12.92%. The main reason for a decline in its sales is that the COVID-19 epidemic has impacted the hospital's overall diagnosis and treatment business. Dolutegravir has a CAGR of 166.14% from 2016 to 2020.

CRI predicts the sales of Dolutegravir will increase from 2021 to 2025 with the increase in the number of AIDS patients. The number of surviving HIV-infected people in China increased from 958,000 in 2019 to 1.045 million in 2020, with a growth rate of 9%. The number of new infections shows an increasing trend. Therefore, sales of Dolutegravir used to treat HIV infection will continue to increase. In addition, with the effective alleviation of the COVID-19 epidemic, the sales of Dolutegravir will have a restorative growth from 2021 to 2025.

Topics Covered:

  • The impact of COVID-19 on China's Dolutegravir market
  • Sales value of China's Dolutegravir 2016-2020
  • Competitive landscape of China's Dolutegravir market
  • Prices of Dolutegravir in China
  • Prices of Dolutegravir in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Dolutegravir market
  • Prospect of China's Dolutegravir market from 2021 to 2025

Table of Contents

1 Relevant Concept of Dolutegravir

  • 1.1 Indications for Dolutegravir
  • 1.2 Development of Dolutegravir in China
  • 1.3 Governmental Approval of Dolutegravir in China
  • 1.4 The Impact of COVID-19 on Dolutegravir sales in China

2 Sales of Dolutegravir in China, 2016-2020

  • 2.1 Sales Value of Dolutegravir
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Dolutegravir
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Dolutegravir by Dosage Form in China, 2016-2020
    • 2.3.1 Tablets
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Dolutegravir Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Dolutegravir Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 ViiV Healthcare BV
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of TIVICAY (ViiV Healthcare BV's Dolutegravir) in China
  • 3.3 Analysis of Other Enterprises

4 Prices of Dolutegravir for Different Manufacturers in China, 2020-2021

  • 4.1 ViiV Healthcare BV (TIVICAY)
  • 4.2 Analysis of Other Enterprises

5 Prospect of Chinese Dolutegravir Market, 2021-2025

  • 5.1 Influential Factors of Chinese Dolutegravir Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Dolutegravir Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Dolutegravir Tablets Registration in China
  • Chart Sales Value of Dolutegravir Tablets over the World
  • Chart Sales Value of Dolutegravir Tablets in China, 2016-2020
  • Chart Sales Value of Dolutegravir Tablets in China by Regions, 2016-2020
  • Chart Sales Volume of Dolutegravir Tablets in China, 2016-2020
  • Chart Sales Volume of Dolutegravir Tablets in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Dolutegravir Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of TIVICAY in China, 2016-2020
  • Chart Referential Prices of TIVICAY in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Dolutegravir in China, 2021-2025
  • Chart Forecast on Sales Volume of Dolutegravir in China, 2021-2025